UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A 4096 channel event-based multielectrode array with asynchronous outputs compatible with neuromorphic processors

Nature communications, 2024-08, Vol.15 (1), p.7163-11

2024

Volltextzugriff (PDF)

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

The oncologist (Dayton, Ohio), 2022-11, Vol.27 (11), p.907-918

2022

Volltextzugriff (PDF)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis

Current oncology (Toronto), 2022-10, Vol.29 (10), p.7524-7536

2022

Volltextzugriff (PDF)

Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

Value in health, 2023-12, Vol.26 (12), p.1689-1696

2023

Volltextzugriff (PDF)

Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities

Current medical research and opinion, 2014-11, Vol.30 (11), p.2355-2364

2014

Volltextzugriff (PDF)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Blood cancer journal (New York), 2022-04, Vol.12 (4), p.71-71, Article 71

2022

Volltextzugriff (PDF)

Treatment patterns and healthcare resource utilization in patients with FLT3‐mutated and wild‐type acute myeloid leukemia: A medical chart study

European journal of haematology, 2019-04, Vol.102 (4), p.341-350

2019

Volltextzugriff (PDF)

Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy

Journal of managed care & specialty pharmacy, 2022-09, Vol.28 (9), p.980-988

2022

Volltextzugriff (PDF)

Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)

Clinical lymphoma, myeloma and leukemia, 2024-03, Vol.24 (3), p.177-186

2024

Volltextzugriff (PDF)

Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study

European journal of haematology, 2022-07, Vol.109 (1), p.58-68

2022

Volltextzugriff (PDF)

Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey

Current medical research and opinion, 2019-05, Vol.35 (5), p.927-935

2019

Volltextzugriff (PDF)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of managed care & specialty pharmacy, 2016-02, Vol.22 (2), p.163-170

2016

Volltextzugriff (PDF)

MP73-13 BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE

The Journal of urology, 2015-04, Vol.193 (4), p.e934-e935

2015

Volltextzugriff (PDF)

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

Journal of medical economics, 2017-02, Vol.20 (2), p.121-128

2017

Volltextzugriff (PDF)

Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder

Journal of medical economics, 2012-11, Vol.15 (s1), p.35-44

2012

Volltextzugriff (PDF)

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP

HemaSphere, 2023-08, Vol.7 (S3), p.e925140d

2023

Volltextzugriff (PDF)

Manufacturing low dissipation superconducting quantum processors

2019 IEEE International Electron Devices Meeting (IEDM), 2019, p.31.1.1-31.1.4

2019

Volltextzugriff (PDF)

Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities

International urology and nephrology, 2014, Vol.46 (1), p.285-296

2014

Volltextzugriff (PDF)

Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the United States

Blood, 2023-11, Vol.142 (Supplement 1), p.7415-7415

2023

Volltextzugriff (PDF)

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine

Blood, 2023-11, Vol.142 (Supplement 1), p.6472-6472

2023

Volltextzugriff (PDF)

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE‐A LONG‐TERM FOLLOW UP

HemaSphere, 2023-08, Vol.7, p.n/a

2023

Volltextzugriff (PDF)

Use of Antimuscarinics in Long Term Care Facility Residents with Urinary Incontinence

Journal of the American Medical Directors Association, 2011, Vol.12 (3), p.B28-B29

2011

Volltextzugriff (PDF)

Unmet Medical Needs Amongst Older Patients Aged ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting

Blood, 2023-11, Vol.142 (Supplement 1), p.3814-3814

2023

Volltextzugriff (PDF)

The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States

Blood, 2023-11, Vol.142 (Supplement 1), p.2436-2436

2023

Volltextzugriff (PDF)

Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.3282-3283

2022

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Englisch
(71)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(17)
Humans
(13)
Male
(8)
Adult
(7)
Aged
(7)
Acute Myeloid Leukemia
(6)
Health Care Sciences & Services
(5)
Leukemia, Myeloid, Acute - Drug Therapy
(5)
Middle Aged
(5)
Oncology
(5)
United States
(5)
Chemotherapy
(4)
Female
(4)
Hematology
(4)
Methods
(4)
Technology
(4)
Azacitidine - Therapeutic Use
(3)
Comorbidity
(3)
General & Internal Medicine
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A 4096 channel event-based multielectrode array with asynchronous outputs compatible with neuromorphic processors

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis

Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Treatment patterns and healthcare resource utilization in patients with FLT3‐mutated and wild‐type acute myeloid leukemia: A medical chart study

Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy

Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)

Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study

Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

MP73-13 BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP

Manufacturing low dissipation superconducting quantum processors

Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities

Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the United States

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE‐A LONG‐TERM FOLLOW UP

Use of Antimuscarinics in Long Term Care Facility Residents with Urinary Incontinence

Unmet Medical Needs Amongst Older Patients Aged ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting

The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States

Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia

Suchergebnisse filtern